Literature DB >> 22490335

Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis.

Javeed Iqbal1, Yulei Shen, Yanyan Liu, Kai Fu, Elaine S Jaffe, Cuiling Liu, Zhongfeng Liu, Cynthia M Lachel, Karen Deffenbacher, Timothy C Greiner, Julie M Vose, Sharathkumar Bhagavathi, Louis M Staudt, Lisa Rimsza, Andreas Rosenwald, German Ott, Jan Delabie, Elias Campo, Rita M Braziel, James R Cook, Raymond R Tubbs, Randy D Gascoyne, James O Armitage, Dennis D Weisenburger, Timothy W McKeithan, Wing C Chan.   

Abstract

miRNA deregulation has been implicated in the pathogenesis of mantle cell lymphoma (MCL). Using a high-throughput quantitative real-time PCR platform, we performed miRNA profiling on cyclin D1-positive MCL (n = 30) and cyclin D1-negative MCL (n = 7) and compared them with small lymphocytic leukemia/lymphoma (n = 12), aggressive B-cell lymphomas (n = 138), normal B-cell subsets, and stromal cells. We identified a 19-miRNA classifier that included 6 up-regulated miRNAs and 13 down regulated miRNA that was able to distinguish MCL from other aggressive lymphomas. Some of the up-regulated miRNAs are highly expressed in naive B cells. This miRNA classifier showed consistent results in formalin-fixed paraffin-embedded tissues and was able to distinguish cyclin D1-negative MCL from other lymphomas. A 26-miRNA classifier could distinguish MCL from small lymphocytic leukemia/lymphoma, dominated by 23 up-regulated miRNAs in MCL. Unsupervised hierarchical clustering of MCL patients demonstrated a cluster characterized by high expression of miRNAs from the polycistronic miR17-92 cluster and its paralogs, miR-106a-363 and miR-106b-25, and associated with high proliferation gene signature. The other clusters showed enrichment of stroma-associated miRNAs, and also had higher expression of stroma-associated genes. Our clinical outcome analysis in the present study suggested that miRNAs can serve as prognosticators.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22490335      PMCID: PMC3367895          DOI: 10.1182/blood-2011-07-370122

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism.

Authors:  T Reya; M O'Riordan; R Okamura; E Devaney; K Willert; R Nusse; R Grosschedl
Journal:  Immunity       Date:  2000-07       Impact factor: 31.745

2.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

3.  The canonical Wnt pathway shapes niches supportive of hematopoietic stem/progenitor cells.

Authors:  Michiko Ichii; Mark Barton Frank; Renato V Iozzo; Paul W Kincade
Journal:  Blood       Date:  2011-11-23       Impact factor: 22.113

4.  Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants.

Authors:  S Beà; M Ribas; J M Hernández; F Bosch; M Pinyol; L Hernández; J L García; T Flores; M González; A López-Guillermo; M A Piris; A Cardesa; E Montserrat; R Miró; E Campo
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

5.  Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.

Authors:  Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Sandeep Dave; George Wright; Andreas Rosenwald; Michael Chiorazzi; Javeed Iqbal; Stefan Gesk; Reiner Siebert; Daphne De Jong; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; German Ott; Bhavana J Dave; Warren G Sanger; Lynette M Smith; Lisa Rimsza; Rita M Braziel; H Konrad Müller-Hermelink; Elias Campo; Randy D Gascoyne; Louis M Staudt; Wing C Chan
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

6.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.

Authors:  Jenny Orchard; Richard Garand; Zadie Davis; Gavin Babbage; Surinder Sahota; Estella Matutes; Daniel Catovsky; Peter W Thomas; Hervé Avet-Loiseau; David Oscier
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

7.  Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue.

Authors:  Huiling Liang; Qin Chen; Andrew H Coles; Stephen J Anderson; German Pihan; Allan Bradley; Rachel Gerstein; Roland Jurecic; Stephen N Jones
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

8.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia.

Authors:  Desheng Lu; Yandong Zhao; Rommel Tawatao; Howard B Cottam; Malini Sen; Lorenzo M Leoni; Thomas J Kipps; Maripat Corr; Dennis A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

9.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Authors:  Sandeep S Dave; George Wright; Bruce Tan; Andreas Rosenwald; Randy D Gascoyne; Wing C Chan; Richard I Fisher; Rita M Braziel; Lisa M Rimsza; Thomas M Grogan; Thomas P Miller; Michael LeBlanc; Timothy C Greiner; Dennis D Weisenburger; James C Lynch; Julie Vose; James O Armitage; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Joseph M Connors; Peter M Lansdorp; Qin Ouyang; T Andrew Lister; Andrew J Davies; Andrew J Norton; H Konrad Muller-Hermelink; German Ott; Elias Campo; Emilio Montserrat; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Liming Yang; John Powell; Hong Zhao; Neta Goldschmidt; Michael Chiorazzi; Louis M Staudt
Journal:  N Engl J Med       Date:  2004-11-18       Impact factor: 91.245

10.  Semi-supervised methods to predict patient survival from gene expression data.

Authors:  Eric Bair; Robert Tibshirani
Journal:  PLoS Biol       Date:  2004-04-13       Impact factor: 8.029

View more
  37 in total

1.  Predictive value of microRNAs as novel biomarkers in detection of lymphoma.

Authors:  Yongjing Wang; Dianshui Sun; Juandong Wang; Aixia Dou; Chengyun Zheng
Journal:  Int J Clin Exp Med       Date:  2015-08-15

2.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

Review 3.  Molecular Insights Into Pathogenesis of Peripheral T Cell Lymphoma: a Review.

Authors:  Waseem Lone; Aisha Alkhiniji; Jayadev Manikkam Umakanthan; Javeed Iqbal
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

4.  MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

Authors:  Cuiling Liu; Javeed Iqbal; Julie Teruya-Feldstein; Yulei Shen; Magdalena Julia Dabrowska; Karen Dybkaer; Megan S Lim; Roberto Piva; Antonella Barreca; Elisa Pellegrino; Elisa Spaccarotella; Cynthia M Lachel; Can Kucuk; Chun-Sun Jiang; Xiaozhou Hu; Sharathkumar Bhagavathi; Timothy C Greiner; Dennis D Weisenburger; Patricia Aoun; Sherrie L Perkins; Timothy W McKeithan; Giorgio Inghirami; Wing C Chan
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

5.  Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets.

Authors:  Alyssa Bouska; Chengfeng Bi; Waseem Lone; Weiwei Zhang; Ambreen Kedwaii; Tayla Heavican; Cynthia M Lachel; Jiayu Yu; Roberto Ferro; Nanees Eldorghamy; Timothy C Greiner; Julie Vose; Dennis D Weisenburger; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Elaine S Jaffe; Rita M Braziel; Reiner Siebert; Rodney R Miles; Sandeep Dave; Anupama Reddy; Jan Delabie; Louis M Staudt; Joo Y Song; Timothy W McKeithan; Kai Fu; Michael Green; Wing C Chan; Javeed Iqbal
Journal:  Blood       Date:  2017-08-11       Impact factor: 22.113

6.  The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.

Authors:  S Robinson; P Dreger; D Caballero; P Corradini; C Geisler; M Ghielmini; S Le Gouill; E Kimby; S Rule; U Vitolo; M Dreyling; O Hermine
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

7.  Genomic imbalances and microRNA transcriptional profiles in patients with mycosis fungoides.

Authors:  Fuad Huaman Garaicoa; Alejandro Roisman; Mariana Arias; Carla Trila; Miguel Fridmanis; Alejandra Abeldaño; Silvia Vanzulli; Marina Narbaitz; Irma Slavutsky
Journal:  Tumour Biol       Date:  2016-07-29

Review 8.  Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.

Authors:  Rong-Li Zheng; Yu-Jie Jiang; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 9.  Risk factors for etiology and prognosis of mantle cell lymphoma.

Authors:  Yu Wang; Shuangge Ma
Journal:  Expert Rev Hematol       Date:  2014-02-22       Impact factor: 2.929

10.  Non-Hodgkin's lymphomas, version 4.2014.

Authors:  Andrew D Zelenetz; Leo I Gordon; William G Wierda; Jeremy S Abramson; Ranjana H Advani; C Babis Andreadis; Nancy Bartlett; John C Byrd; Myron S Czuczman; Luis E Fayad; Richard I Fisher; Martha J Glenn; Nancy Lee Harris; Richard T Hoppe; Steven M Horwitz; Christopher R Kelsey; Youn H Kim; Susan Krivacic; Ann S LaCasce; Auayporn Nademanee; Pierluigi Porcu; Oliver Press; Rachel Rabinovitch; Nishitha Reddy; Erin Reid; Ayman A Saad; Lubomir Sokol; Lode J Swinnen; Christina Tsien; Julie M Vose; Joachim Yahalom; Nadeem Zafar; Mary Dwyer; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2014-09       Impact factor: 11.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.